COVID-19 posed a major challenge to the global health agenda, with pharmaceutical manufacturers shifting their production and distribution processes to rapidly respond to escalating demands for vaccines and medical products. The pandemic also revitalized the importance of sound pharmacovigilance (PV) systems and national regulatory authorities (NRA) to ensure the safety, quality, and efficacy of vaccines and drugs.